The endocannabinoidome in neuropsychiatry: Opportunities and potential risks
Gerwyn Morris, Ken Walder, Stefan Kloiber, Paul Amminger, Michael Berk, Chiara C Bortolasci, Michael Maes, Basant K Puri, Andre F Carvalho
PHARMACOLOGICAL RESEARCH | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD | Published : 2021
The endocannabinoid system (ECS) comprises two cognate endocannabinoid receptors referred to as CB1R and CB2R. ECS dysregulation is apparent in neurodegenerative/neuro-psychiatric disorders including but not limited to schizophrenia, major depressive disorder and potentially bipolar disorder. The aim of this paper is to review mechanisms whereby both receptors may interact with neuro-immune and neuro-oxidative pathways, which play a pathophysiological role in these disorders. CB1R is located in the presynaptic terminals of GABAergic, glutamatergic, cholinergic, noradrenergic and serotonergic neurons where it regulates the retrograde suppression of neurotransmission. CB1R plays a key role in ..View full abstract
Awarded by NHMRC Senior Principal Research Fellowship
MB is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072).